PharmaMar Launches Aplidin Quadruple Combo Trial in Myeloma
PharmaMar is launching a clinical trial to explore its investigational therapy Aplidin (plitidepsin) in a quadruple combination treatment for multiple myeloma. The four compounds involved…
News
VAX-DC/MM Cell Therapy Shows Promise in Relapsed or Refractory Myeloma, Lymphoma Patients
NantKwest’s Vax-DC/MM cell therapy has induced a partial or complete response in 42 percent of relapsed or refractory multiple myeloma (MM) and lymphoma patients in a…
Imbruvica Becomes 1st FDA-Approved Therapy for Graft-Versus-Host-Disease in Adults
The U.S. Food and Drug Administration (FDA) has approved Imbruvica (ibrutinib) for the treatment of chronic graft-versus-host-disease (cGVHD), a common complication of stem cell or bone…
STRO-001 Eliminates or Slows Growth of Myeloma and Lymphoma in Mice, Studies Show
Sutro Biopharma‘s STRO-001 eliminates or significantly slows the growth of non-Hodgkin lymphoma and multiple myeloma tumors, studies in mice indicate. Sutro expects the results to support…
Revlimid Therapy May Delay Myeloma Progression and Increase Survival
Revlimid (lenalidomide) therapy maintenance has been shown to delay disease progression and extend survival in newly diagnosed multiple myeloma (NDMM) patients who receive a transplant…
Stem Cell Transplants Work for Many Myeloma Patients Who Fail to Respond to First-line Therapies, Study Finds
Stem cell transplants derived from patients’ own bone marrow are a safe and effective treatment for those with multiple myeloma who fail to respond to first-line…
Systemic Gaps in Cancer Care Are Detrimental to Patient Outcomes, Survey Finds
The Cancer Support Community (CSC), a nonprofit advocacy organization, recently released a research report about the emotional, social, and financial burdens on cancer patients. The…
Kyprolis-Dexamethasone Combo Allows Relapsed Myeloma Patients to Live Longer, Amgen Says
Kyprolis (carfilzomib), when given with dexamethasone, lets relapsed myeloma patients live an average 7.6 months longer than those treated with  Velcade (bortezomib) with dexamethasone — information that …
Kyprolis Regimen Reduces Risk of Death in Relapsed Multiple Myeloma Patients, Studies Show
Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard regimen of Revlimid (lenalidomide) and dexamethasone reduced the risk of…
KD025 Shows Promise for Chronic Graft-Versus-Host Disease, a Common Complication of Stem Cell Transplants
Kadmon reports that the first patient group treated in a Phase 2 trial of its drug KD025 for chronic graft-versus-host disease after going through…
